198 related articles for article (PubMed ID: 27380866)
1. Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines.
Xiao A; Zheng XJ; Song C; Gui Y; Huo CX; Ye XS
Org Biomol Chem; 2016 Jul; 14(30):7226-37. PubMed ID: 27380866
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.
Wu X; McKay C; Pett C; Yu J; Schorlemer M; Ramadan S; Lang S; Behren S; Westerlind U; Finn MG; Huang X
ACS Chem Biol; 2019 Oct; 14(10):2176-2184. PubMed ID: 31498587
[TBL] [Abstract][Full Text] [Related]
3. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
4. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
Sarkar S; Salyer AC; Wall KA; Sucheck SJ
Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
[TBL] [Abstract][Full Text] [Related]
6. Synthetic and immunological studies of N-acyl modified S-linked STn derivatives as anticancer vaccine candidates.
Huo CX; Zheng XJ; Xiao A; Liu CC; Sun S; Lv Z; Ye XS
Org Biomol Chem; 2015 Mar; 13(12):3677-90. PubMed ID: 25679360
[TBL] [Abstract][Full Text] [Related]
7. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
ChemMedChem; 2017 Sep; 12(17):1424-1428. PubMed ID: 28675699
[TBL] [Abstract][Full Text] [Related]
9. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
11. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
[TBL] [Abstract][Full Text] [Related]
12. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
Kagan E; Ragupathi G; Yi SS; Reis CA; Gildersleeve J; Kahne D; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2005 May; 54(5):424-30. PubMed ID: 15625606
[TBL] [Abstract][Full Text] [Related]
15. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of MUC1-derived glycopeptide bearing a novel triazole STn analog.
Marchiori MF; Bortot LO; Carvalho I; Campo VL
Carbohydr Res; 2020 Dec; 498():108155. PubMed ID: 33010570
[TBL] [Abstract][Full Text] [Related]
17. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
18. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
Holmberg LA; Oparin DV; Gooley T; Sandmaier BM
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S144-51. PubMed ID: 12620152
[TBL] [Abstract][Full Text] [Related]
19. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
